Iqvia Holdings Inc. Stock

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse 16:00:02 2024-04-12 EDT 5-day change 1st Jan Change
234.2 USD -1.59% Intraday chart for Iqvia Holdings Inc. -2.99% +1.23%
Sales 2024 * 15.53B 21.39B Sales 2025 * 16.66B 22.95B Capitalization 42.63B 58.71B
Net income 2024 * 1.33B 1.83B Net income 2025 * 1.58B 2.17B EV / Sales 2024 * 3.52 x
Net Debt 2024 * 12.07B 16.63B Net Debt 2025 * 11.65B 16.05B EV / Sales 2025 * 3.26 x
P/E ratio 2024 *
32.1 x
P/E ratio 2025 *
26.9 x
Employees 87,000
Yield 2024 *
-
Yield 2025 *
-
Free-Float 69.76%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Iqvia Holdings Inc.

1 day-1.59%
1 week-2.99%
Current month-7.38%
1 month-8.38%
3 months+9.53%
6 months+17.49%
Current year+1.23%
More quotes
1 week
232.86
Extreme 232.86
247.01
1 month
232.86
Extreme 232.86
256.34
Current year
205.38
Extreme 205.38
261.73
1 year
167.42
Extreme 167.42
261.73
3 years
165.75
Extreme 165.75
285.61
5 years
81.79
Extreme 81.79
285.61
10 years
46.27
Extreme 46.27
285.61
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 16-10-02
Director of Finance/CFO 63 20-07-31
Chief Operating Officer 51 17-06-30
Members of the board TitleAgeSince
Director/Board Member 67 16-10-02
Director/Board Member 68 17-07-26
Chief Executive Officer 62 16-10-02
More insiders
Date Price Change Volume
24-04-12 234.2 -1.59% 932,313
24-04-11 238 -0.58% 658,356
24-04-10 239.4 -2.41% 534,636
24-04-09 245.3 +1.59% 548,706
24-04-08 241.5 +0.02% 495,441

Delayed Quote Nyse, April 12, 2024 at 04:00 pm

More quotes
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
234.2 USD
Average target price
275.4 USD
Spread / Average Target
+17.57%
Consensus